Prevalence of plasma lipid abnormalities and its association with glucose metabolism in Spain: the di@bet.es study

Clin Investig Arterioscler. 2014 May-Jun;26(3):107-14. doi: 10.1016/j.arteri.2013.12.001. Epub 2014 Jan 23.

Abstract

Introduction: Dyslipidemia is a significant contributor to the elevated CVD risk observed in type 2 diabetes mellitus. We assessed the prevalence of dyslipidemia and its association with glucose metabolism status in a representative sample of the adult population in Spain and the percentage of subjects at guideline-recommended LDL-C goals.

Material and methods: The di@bet.es study is a national, cross-sectional population-based survey of 5728 adults.

Results: A total of 4776 subjects were studied. Dyslipidemia was diagnosed in 56.8% of subjects; only 13.2% of subjects were treated with lipid lowering drugs. Lipid abnormalities were found in 56.8% of Spanish adults: 23.3% with high LDL-C, 21.5% high TG, 35.8% high non-HDL-C, and 17.2% low HDL-C. Most normal subjects showed an LDL-C ≤ 3.36 mmol/l. Pre-diabetics presented similar proportion when considering a goal of 3.36 mmol/l, but only 35% of them reached an LDL-C goal ≤ 2.6 mmol/l. Finally, 45.3% of diabetics had an LDL-C ≤ 2.6 mmol/l, and only 11.3% achieved an LDL-C ≤ 1.8 mmol/l.

Conclusions: Our study demonstrates a high prevalence of dyslipidemia in the adult Spanish population, and a low use of lipid-lowering drugs. Moreover, the number of subjects achieving their corresponding LDL-C goal is small, particularly in subjects at high cardiovascular risk, such as diabetics.

Keywords: Diabetes; Dislipidemia; Dyslipidemia; LDL-C goal; Objetivo de cLDL.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Cardiovascular Diseases / etiology
  • Cholesterol, HDL / blood
  • Cholesterol, LDL / blood*
  • Cross-Sectional Studies
  • Diabetes Mellitus, Type 2 / blood*
  • Dyslipidemias / complications
  • Dyslipidemias / drug therapy
  • Dyslipidemias / epidemiology*
  • Female
  • Glucose / metabolism*
  • Humans
  • Hypolipidemic Agents / therapeutic use
  • Male
  • Middle Aged
  • Prediabetic State / blood
  • Prevalence
  • Risk Factors
  • Spain / epidemiology
  • Young Adult

Substances

  • Cholesterol, HDL
  • Cholesterol, LDL
  • Hypolipidemic Agents
  • Glucose